Unlike systemic fat burners, which often lead to overstimulation of the nervous system, AOD-9604 acts at the cellular level, sending a signal directly to adipocytes (fat cells) ordering them to release stored fatty acids
Novo Nordisk and Eli Lilly are setting a precedent and if it pays off then we can expect that other pharmaceutical companies will follow suit
Patient reported data suggest that mild to moderate nausea and related symptoms often begin to settle over 28 weeks, with further improvement over several months for many but not all patients
Although searches for Cagrilintide weight loss, Cagrilintide peptide benefits, and Cagrilintide peptide dosage are common, these topics relate to ongoing scientific investigation
PubMed laboratory research record [PMID: 24112071] PubMed record related to this compound for laboratory literature review
Frontiers in Bioengineering and Biotechnology, 9 , Article 677576